Bayer (BAYRY) told U.S. lawmakers it could stop selling its Roundup weedkiller unless legal protection can be strengthened against product liability litigation, Patricia Weiss and Ludwig Burger of Reuters report, citing a person close to the matter. Bayer has paid about $10B to settle claims that Roundup causes cancer, and a further 67,000 cases are pending for which the company has set aside $5.9B in legal provisions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer expects improved performance from 2026 onwards
- Bayer sees FY25 core EPS EUR 4.50-EUR 5.00 on currency-adjusted basis
- Bayer sees FY25 sales roughly at prior-year level
- Bayer reports Q4 core EPS EUR 1.05 vs. EUR 1.85 last year
- Bayer’s Financial Challenges and Mixed Divisional Performance Lead to Hold Rating